Peppermint oil for IBS: what the pooled trials show, and what the newest trial did not

Study at a glance

Alammar and colleagues systematically searched five databases for randomised trials of peppermint oil in IBS and pooled 12 of them, covering 835 patients. Peppermint oil was associated with a more than two-fold higher chance of global symptom improvement versus placebo (RR 2.39, 95% CI 1.93 to 2.97) and a 78% higher chance of abdominal pain improvement (RR 1.78, 95% CI 1.43 to 2.20), with no statistically significant excess of adverse events. The headline numbers are striking; the trials behind them are mostly small, and the largest rigorous trial published since then tells a more cautious story.

What they did

The authors pre-registered a protocol (PROSPERO CRD42016050917) and searched MEDLINE, Cochrane CENTRAL, ClinicalTrials.gov, EMBASE and Web of Science for randomised controlled trials of peppermint oil in IBS. Eligible trials were appraised with the Cochrane risk-of-bias tool. The primary outcomes were global improvement in IBS symptoms and improvement in abdominal pain, analysed with random-effects meta-analysis. Adverse events were pooled across trials that reported them.

What they found

Twelve trials with 835 patients met the inclusion criteria. For global symptoms, seven trials contributed data on 253 peppermint oil and 254 placebo patients; the pooled risk ratio favoured peppermint oil at 2.39 (95% CI 1.93 to 2.97) with no heterogeneity (I² = 0%). For abdominal pain, six trials (278 vs 278 patients) gave a pooled RR of 1.78 (95% CI 1.43 to 2.20), again with I² = 0%. Reported adverse events ran 9.3% on peppermint oil versus 6.1% on placebo across eight trials, a difference that did not reach statistical significance (RR 1.40, 95% CI 0.87 to 2.26). The authors calculated a number needed to treat of three for global symptoms and four for pain, and described peppermint oil as a safe and effective option for adults with IBS.

Two subsequent papers are worth reading alongside it. A 2020 network meta-analysis of 51 trials of “traditional” IBS therapies (soluble fibre, antispasmodics, peppermint oil, gut-brain neuromodulators) ranked peppermint oil capsules first for global symptom improvement (RR of failing to improve 0.63, 95% CI 0.48 to 0.83), but only 13 of the 51 trials were at low risk of bias, and the authors cautioned that this leaves considerable uncertainty (PMID: 31859183). Then the PERSUADE trial, a 190-patient, double-blind, eight-week Dutch study using FDA- and EMA-style endpoints, found that neither small-intestinal-release nor ileocolonic-release peppermint oil beat placebo on the primary endpoints: abdominal pain response was 46.8% vs 34.4% for placebo (p = 0.17) with the small-intestinal formulation, and overall relief did not differ. Secondary outcomes (pain, discomfort, severity) did favour the small-intestinal formulation, and mild adverse events were more common with peppermint (PMID: 31470006).

Strengths

• A registered protocol, a broad multi-database search, and formal risk-of-bias assessment.
• Consistency: I² of 0% for both primary outcomes means the included trials pointed the same way, which is unusual in IBS.
• The safety analysis pooled actual event counts rather than relying on narrative reporting.
• The effect was large enough that even substantial bias would be unlikely to erase it entirely, which is partly why guidelines still list peppermint oil as an option.

Limitations

• Small, older trials. Most of the included studies enrolled well under 100 patients, and several predate modern diagnostic criteria and regulatory endpoints. Small-study effects tend to inflate pooled estimates, and the network meta-analysis that followed rated most of the evidence base as being at unclear or high risk of bias.
• Heterogeneous products and doses. Enteric-coated capsules of varying strength, different treatment lengths, and different outcome definitions were pooled. “Peppermint oil” is not one intervention.
• Outcome definitions. Global improvement was often a single patient-reported yes/no, which is more responsive than the composite endpoints regulators now require. PERSUADE’s failure on those stricter endpoints, with a respectable placebo response of 34%, illustrates the gap.
• An I² of 0% across small trials can also reflect low power to detect heterogeneity rather than true agreement.
• Blinding is imperfect: peppermint has a taste and can cause reflux, so some participants may guess their allocation.
• The lead author discloses an editorial role at the publishing journal; the review reports no industry funding.

What it means

A fair reading is that peppermint oil may help global symptoms and abdominal pain in IBS, that it appears low-risk, and that the pooled evidence is consistent but built on small trials of uneven quality. The 2021 ACG guideline reflects exactly this: a conditional suggestion in favour, on low-quality evidence. The largest modern trial did not confirm the benefit on strict regulatory endpoints, though it did show modest improvements on secondary measures, so expectations should be calibrated toward “worth a try” rather than “reliably effective.”

Readers should not take an NNT of three at face value; that figure comes from older, lenient endpoints. They should also expect heartburn or reflux as the main nuisance side effect, particularly with non-enteric-coated products. Anyone with reflux disease, gallstones, or who is pregnant should raise peppermint oil with a clinician or pharmacist before using it, and it is a reasonable topic to discuss when reviewing first-line IBS options.

References

• Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019. PMID: 30654773
• Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020. PMID: 31859183
• Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2020. PMID: 31470006